Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells

被引:44
作者
Cerutti, A
Kim, EC
Shah, S
Schattner, EJ
Zan, H
Schaffer, A
Casali, P
机构
[1] Cornell Univ, Weill Med Coll, Dept Pathol, Div Mol Immunol, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Grad Sch Med Sci, Program Immunol, New York, NY 10021 USA
[3] Cornell Univ, Weill Med Coll, Dept Med, Div Hematol, New York, NY 10021 USA
关键词
D O I
10.1038/84254
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic lymphocytic leukemia (CLL) is associated with impaired immunoglobulin (Ig) class-switching from IgM to IgG and IgA, a defect that leads to recurrent infections,When activated in the presence of leukemic CLL B cells, T cells rapidly up-regulate CD30 through an OX40 ligand and interleukin 4 (IL-4)-dependent mechanism. These leukemia-induced CD30(+) T cells inhibit CD40 ligand (CD40L)-mediated S mu-->S gamma and S mu-->S alpha class-switch DNA recombination (CSR) by engaging CD30 ligand (CD30L), a molecule that interferes with the assembly of the CD40-tumor necrosis factor receptor-associated factor (TRAF) complex in nonmalignant IgD(+) B cells. In addition, engagement of T cell CD30 by CD30L on neoplastic CLL B cells down-regulates the CD3-induced expression of CD40L. These findings indicate that, in CLL, abnormal CD30-CD30L interaction impairs IgG and IgA production by interfering with the CD40-mediated differentiation of nonmalignant B cells.
引用
收藏
页码:150 / 156
页数:7
相关论文
共 51 条
  • [1] ADERKA D, 1993, BLOOD, V81, P2076
  • [2] Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice
    Amakawa, R
    Hakem, A
    Kundig, TM
    Matsuyama, T
    Simard, JJL
    Timms, E
    Wakeham, A
    Mittruecker, HW
    Griesser, H
    Takimoto, H
    Schmits, R
    Shahinian, A
    Ohashi, PS
    Penninger, JM
    Mak, TW
    [J]. CELL, 1996, 84 (04) : 551 - 562
  • [3] TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: Transcriptional activation of I kappa B alpha
    Arsura, M
    Wu, M
    Sonenshein, GE
    [J]. IMMUNITY, 1996, 5 (01) : 31 - 40
  • [4] CD40 ligand (CD154) triggers a short-term CD4+ T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis
    Blair, PJ
    Riley, JL
    Harlan, DM
    Abe, R
    Tadaki, DK
    Hoffmann, SC
    White, L
    Francomano, T
    Perfetto, SJ
    Kirk, AD
    June, CH
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (04) : 651 - 660
  • [5] BOWEN MA, 1993, J IMMUNOL, V151, P5896
  • [6] Acquired CD40-ligand deficiency in chronic lymphocytic leukemia
    Cantwell, M
    Hua, T
    Pappas, J
    Kipps, TJ
    [J]. NATURE MEDICINE, 1997, 3 (09) : 984 - 989
  • [7] CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells
    Cerutti, A
    Schaffer, A
    Shah, S
    Zan, H
    Liou, HC
    Goodwin, RG
    Casali, P
    [J]. IMMUNITY, 1998, 9 (02) : 247 - 256
  • [8] Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells
    Cerutti, A
    Schaffer, A
    Goodwin, RG
    Shah, S
    Zan, H
    Ely, S
    Casali, P
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (02) : 786 - 794
  • [9] Phosphorylation of TRAF2 inhibits binding to the CD40 cytoplasmic domain
    Chaudhuri, A
    Orme, S
    Vo, T
    Wang, WH
    Cherayil, BJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 256 (03) : 620 - 625
  • [10] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
    Cheson, BD
    Bennett, JM
    Grever, M
    Kay, N
    Keating, MJ
    OBrien, S
    Rai, KR
    [J]. BLOOD, 1996, 87 (12) : 4990 - 4997